Kezar Life Sciences (NASDAQ:KZR) Shares Down 6.2%

Kezar Life Sciences, Inc. (NASDAQ:KZR) shares dropped 6.2% during trading on Monday . The company traded as low as $0.80 and last traded at $0.81. Approximately 578,223 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 710,630 shares. The stock had previously closed at $0.86.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Kezar Life Sciences in a research report on Friday, March 15th.

Kezar Life Sciences Trading Up 4.3 %

The company’s 50 day moving average price is $0.90 and its 200 day moving average price is $0.89. The company has a market cap of $59.45 million, a price-to-earnings ratio of -0.58 and a beta of 0.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 11.66 and a current ratio of 11.66.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. Research analysts anticipate that Kezar Life Sciences, Inc. will post -1.26 EPS for the current year.

Hedge Funds Weigh In On Kezar Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. RVW Wealth LLC bought a new stake in Kezar Life Sciences during the 3rd quarter worth approximately $28,000. Amundi bought a new stake in Kezar Life Sciences during the 4th quarter worth approximately $32,000. SG Americas Securities LLC bought a new stake in shares of Kezar Life Sciences in the 3rd quarter valued at $39,000. Public Employees Retirement System of Ohio bought a new position in Kezar Life Sciences during the second quarter worth $45,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Kezar Life Sciences in the first quarter valued at about $45,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.